Peanut Oral Immunotherapy in Children

PHASE2CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

August 13, 2013

Primary Completion Date

July 2, 2018

Study Completion Date

December 21, 2018

Conditions
Peanut Hypersensitivity
Interventions
BIOLOGICAL

Peanut Oral Immunotherapy - Liquid Extract

Used during initial dose escalation for doses 0.1 to 0.8 mg.

BIOLOGICAL

Placebo for Peanut Oral Immunotherapy - Liquid Extract form

Similar in appearance, texture, and taste to peanut liquid extract.

BIOLOGICAL

Peanut Oral Immunotherapy - Peanut Flour

This will be used for the remainder of dose escalation, build-up, and maintenance.

BIOLOGICAL

Placebo for Peanut Oral Immunotherapy - Peanut Flour

Similar in appearance, texture, and taste to peanut flour.

Trial Locations (5)

10029

Mount Sinai School of Medicine, New York

21287

Johns Hopkins Hospital, Baltimore

27599

UNC Chapel-Hill, Chapel Hill

72202

University of Arkansas for Medical Sciences: Arkansas Children's Hospital, Little Rock

94040

Stanford University School of Medicine, Stanford

All Listed Sponsors
collaborator

Immune Tolerance Network (ITN)

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01867671 - Peanut Oral Immunotherapy in Children | Biotech Hunter | Biotech Hunter